BEAM THERAPEUTICS INC (BEAM)
US07373V1052 - Common Stock
We assign a fundamental rating of 4 out of 10 to BEAM. BEAM was compared to 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BEAM as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, BEAM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year BEAM has reported negative net income.
BEAM had a negative operating cash flow in the past year.
BEAM had negative earnings in each of the past 5 years.
In the past 5 years BEAM reported 4 times negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of -9.08%, BEAM belongs to the best of the industry, outperforming 89.59% of the companies in the same industry.
Looking at the Return On Equity, with a value of -13.51%, BEAM belongs to the top of the industry, outperforming 90.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.08% | ||
| ROE | -13.51% | ||
| ROIC | N/A |
ROA(3y)-18.59%
ROA(5y)-31.49%
ROE(3y)-32.58%
ROE(5y)-53.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for BEAM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BEAM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BEAM has more shares outstanding
BEAM has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BEAM has an improved debt to assets ratio.
2.2 Solvency
BEAM has an Altman-Z score of 1.87. This is not the best score and indicates that BEAM is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.87, BEAM is in the better half of the industry, outperforming 69.45% of the companies in the same industry.
BEAM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.87 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
BEAM has a Current Ratio of 5.89. This indicates that BEAM is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BEAM (5.89) is better than 61.60% of its industry peers.
BEAM has a Quick Ratio of 5.89. This indicates that BEAM is financially healthy and has no problem in meeting its short term obligations.
BEAM's Quick ratio of 5.89 is fine compared to the rest of the industry. BEAM outperforms 62.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.89 | ||
| Quick Ratio | 5.89 |
3. Growth
3.1 Past
BEAM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.00%, which is quite impressive.
BEAM shows a strong growth in Revenue. In the last year, the Revenue has grown by 520.01%.
The Revenue has been growing by 2563.03% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)54%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q420.37%
Revenue 1Y (TTM)520.01%
Revenue growth 3Y2563.03%
Revenue growth 5YN/A
Revenue growth Q2Q1477.8%
3.2 Future
The Earnings Per Share is expected to grow by 2.45% on average over the next years.
Based on estimates for the next years, BEAM will show a very strong growth in Revenue. The Revenue will grow by 48.34% on average per year.
EPS Next Y-188.59%
EPS Next 2Y-64.92%
EPS Next 3Y-43.16%
EPS Next 5Y2.45%
Revenue Next Year-19.93%
Revenue Next 2Y-9.9%
Revenue Next 3Y-15.45%
Revenue Next 5Y48.34%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
BEAM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BEAM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as BEAM's earnings are expected to decrease with -43.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-64.92%
EPS Next 3Y-43.16%
5. Dividend
5.1 Amount
No dividends for BEAM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BEAM THERAPEUTICS INC
NASDAQ:BEAM (5/3/2024, 7:00:01 PM)
After market: 23.13 0 (0%)23.13
+0.41 (+1.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.89B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.08% | ||
| ROE | -13.51% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.89 | ||
| Quick Ratio | 5.89 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)54%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-188.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)520.01%
Revenue growth 3Y2563.03%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y